Exploratory Analysis

---

 This exploratory analysis compares three drastically different at-risk populations' reaction to the coronavirus crisis (including lexicon themes, volume of related conversations, and hot topics). The three therapeutic areas of focus in the analysis are:

1. Alzheimer's patients (the elderly)
2. Cystic fibrosis patients (the immunocompromised)
3. NAFLD patients (those with many comorbid conditions)

In this exploratory analysis, NetNoggin® revealed which biotech and pharmaceutical companies (developing NASH/NAFL drug candidates) are driving conversations online and how the community is reacting to their progress. The top five companies that drove the most conversation volume during the one year retrospective listening period were:

1. Gilead Sciences
2. Genfit
3. Intercept Pharmaceuticals
4. Viking Therapeutics
5. Pfizer

In this exploratory analysis, “Psychographics for TRIKAFTA™, the new treatment by Vertex for patients with cystic fibrosis”,  NetNoggin® analyzed big data to better understand attitudes and beliefs from patients and caregivers regarding the approval of TRIKAFTA™ in the cystic fibrosis market. 

This exploratory study revealed healthcare providers (HCPs) in the nonalcoholic steatohepatitis (NASH), including nonalcoholic fatty liver (NAFL), market have multiple unmet needs within:

• Research of NASH (including NAFL), 
• Pediatric nonalcoholic fatty liver disease (NAFLD), 
• Diagnosis and screening, 
• Treatment and management protocols, and 
• Education and awareness for patients and the general community.

In addition, one controversial need debated by HCPs is whether or not pharmacotherapies will solve the NAFLD epidemic. Within the spectrum of beliefs on this subject, most HCPs suggest pharmacotherapies are not needed to cure the disease.

This exploratory study revealed that among those impacted by Alzheimer's, hope of finding a cure is deflating due to recent clinical trial failures. This exploration was a combination of secondary analysis and primary netnographic research. Findings for this explanatory analysis was published on the Journal of Alzheimer's Disease blog.